Detailed introduction to the efficacy and side effects of dupilumab/dalbitux

Dupilumab (dupilumab) is an interleukin-4 receptor alpha antagonist that can simultaneously block the IL-4 and IL-13 signaling pathways to achieve immune regulation. In diseases related to chronic obstructive pulmonary disease, asthma, atopic dermatitis and eosinophilic inflammation, it reduces airway inflammation, improves lung function and reduces acute exacerbations by inhibiting inflammatory responses and regulating immune cell function. The mechanism of action of dupilumab shows obvious advantages in patients with relapsed or refractory disease, especially those with COPD that are poorly controlled by conventional therapies.

In terms of efficacy, dupilumab can reduce the number of acute exacerbations of COPD and improve respiratory symptoms and quality of life. It has also shown significant efficacy in other indications, such as asthma and atopic dermatitis, achieving precise disease control by targeting eosinophilic inflammation and Th2-type immune responses. Its clinical value is not only reflected in alleviating symptoms, but also regulating the immune environment and fundamentally reducing the risk of inflammation recurrence and disease progression.

In terms of side effects, the most common side effects of dupilumab are injection site reactions, mild rash, conjunctivitis and upper respiratory tract infection, which are usually mild to moderate and can be relieved by symptomatic treatment. A small number of patients may develop dry eyes, allergic reactions or immune-related complications, so a detailed assessment of the patient's allergic history and immune status is required before use. Standardized medication and regular follow-up are key to reducing the risk of side effects, including monitoring hematological indicators, lung function and clinical symptoms. Overseas practice shows that through reasonable pretreatment and follow-up management, most patients can obtain long-term benefits from safe and continuous use of dupilumab.

Overall, dupilumab provides a precise immunotherapy for COPD and a variety of eosinophilic inflammation-related diseases. Long-term maintenance injections can achieve disease stabilization and improvement in quality of life. Reasonable side effect management and individualized course design are the core to ensure efficacy and safety.

Reference materials:https://www.drugs.com